ID   INT-MEL-16/1
AC   CVCL_F250
SY   Me9923/P; Me9923p; Me9923; Me 9923; 9923
DR   CLO; CLO_0001015
DR   CLDB; cl141
DR   Cosmic; 720622
DR   Cosmic; 2759875
DR   Wikidata; Q54897761
RX   DOI=10.13130/grazia-giulia_phd2016-02-18;
RX   DOI=10.1007/0-306-46872-7_16;
RX   PubMed=9637706;
CC   HLA typing: A*02; B*41,50; C*w02,06 (PubMed=9637706).
CC   Sequence variation: Mutation; HGNC; HGNC:914; B2M; Simple; p.Asp79fs*6 (c.235_248del14); Zygosity=Homozygous (PubMed=9637706).
CC   Sequence variation: Mutation; HGNC; HGNC:914; B2M; Simple; p.Tyr86Ter (c.258C>G); Zygosity=Homozygous (PubMed=9637706).
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_HE37 ! INT-MEL-16/2
SX   Female
AG   65Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 13
//
RX   DOI=10.13130/grazia-giulia_phd2016-02-18;
RA   Grazia G.;
RT   "Co-targeting of oncogenic and death receptors pathways in human
RT   melanoma: pre-clinical rationale for a pro-apoptotic and anti-angiogenic
RT   strategy.";
RL   Thesis PhD (2015); Universita degli studi di Milano; Milano; Italy.
//
RX   DOI=10.1007/0-306-46872-7_16;
RA   Anichini A., Mortarini R., Vegetti C., Molla A., Borri A., Parmiani G.;
RT   "Melanoma: the Milan melanoma cell lines.";
RL   (In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.283-292; Kluwer Academic Publishers; New York; USA (1999).
//
RX   PubMed=9637706; DOI=10.1172/JCI498; PMCID=PMC508863;
RA   Hicklin D.J., Wang Z.-G., Arienti F., Rivoltini L., Parmiani G.,
RA   Ferrone S.;
RT   "Beta2-microglobulin mutations, HLA class I antigen loss, and tumor
RT   progression in melanoma.";
RL   J. Clin. Invest. 101:2720-2729(1998).
//